ライフサイエンスコーパス: thromboembolic event

1 ricular arrhythmias, 5 cardiac deaths, and 5 thromboembolic events).

2 lder age, smoking, node negativity, or prior thromboembolic event.

3 ascular event, and 14,550 had a first venous thromboembolic event.

4 ntation, new heart failure, stroke, or other thromboembolic event.

5 hemopericardium, and 5 patients (0.7%) had a thromboembolic event.

6 to death, first major haemorrhage, and first thromboembolic event.

7 One patient (1.6%) had a thromboembolic event.

8 ardial infarction, stroke, heart failure, or thromboembolic event.

9 deaths, the probable cause of death was the thromboembolic event.

10 s, non-O blood groups explain >30% of venous thromboembolic events.

11 higher incidence of both venous and arterial thromboembolic events.

12 ia who present with atypical vascular and/or thromboembolic events.

13 ted, including all-cause mortality and fatal thromboembolic events.

14 associated complications of arrhythmias and thromboembolic events.

15 bleeding risk without a favorable effect on thromboembolic events.

16 ular atrial fibrillation is a major cause of thromboembolic events.

17 ), thresholds were stable, and there were no thromboembolic events.

18 lation has been associated with some risk of thromboembolic events.

19 cal patients are at risk for fatal and major thromboembolic events.

20 long-term survival and very low incidence of thromboembolic events.

21 and fractures and increased the incidence of thromboembolic events.

22 with respect to the incidence of bleeding or thromboembolic events.

23 rophylaxis do not have an increased risk for thromboembolic events.

24 al relevance in prophylaxis and treatment of thromboembolic events.

25 f statins (or higher dose statins) on venous thromboembolic events.

26 m 0.68 to 0.72, P<0.0001, for a composite of thromboembolic events.

27 tins substantially reduce the risk of venous thromboembolic events.

28 for translation due to its association with thromboembolic events.

29 of lasofoxifene increased the risk of venous thromboembolic events.

30 , and stroke but an increased risk of venous thromboembolic events.

31 8 patients with AF, we observed 676 incident thromboembolic events.

32 proportional reporting of syncope and venous thromboembolic events.

33 dverse event of grade 3 or worse, especially thromboembolic events.

34 discussed as are recommendations to prevent thromboembolic events.

35 ficacy outcome was the composite of death or thromboembolic events.

36 age, incidence of seizures, and incidence of thromboembolic events.

37 osinophils may be required for prevention of thromboembolic events.

38 ined (HR: 0.34 vs. LT; 95% CI: 0.13 to 0.91) thromboembolic events.

39 safety parameters, including no evidence of thromboembolic events.

40 sease, especially by increasing the risk for thromboembolic events.

41 pathogenesis of atherosclerosis, leading to thromboembolic events.

42 at high risk for arrhythmic sudden death and thromboembolic events.

43 ves during pregnancy is essential to prevent thromboembolic events.

44 carotid artery stenting reduces the rate of thromboembolic events.

45 ted therapy showed significant reductions in thromboembolic events (0.27, 0.12-0.59) and death (0.37,

46 anticoagulated patients experienced nonfatal thromboembolic events (1.1%/year), whereas 13 with apica

47 [<1%]), dyspnoea (nine [2%] vs 38 [7%]), and thromboembolic events (11 [2%] vs 26 [5%]).

48 arrhoea (nine [7%] vs nine [7%]), and venous thromboembolic events (11 [8%] vs six [4%]).

49 ; adjusted IRR, 2.93; 95% CI, 1.54-5.55) for thromboembolic events; 11.86 (95% CI, 7.81-18.01) vs 5.3

50 Thromboembolic events (12.5%), hypertension (12.5%), hyp

51 d superficial surgical-site infections, 2040 thromboembolic events, 1338 myocardial infarctions, and

52 years; 30 of the patients (20%) developed 32 thromboembolic events (15 arterial and 17 venous events)

53 readmissions, followed by cardiovascular or thromboembolic events (18%).

54 [2%] patients), and grade 3 or higher venous thromboembolic events (23 [8%] vs 11 [4%] patients) than

55 There were 39 thromboembolic events (3.7% strokes [n=29] and 1.3% tran

56 , were associated with an increase in venous thromboembolic events (3.8 and 2.9 cases vs. 1.4 cases p

57 idence interval [CI]: 0.5% to 1.0%) definite thromboembolic events (31 strokes) within 30 days (media

58 A total of 71 thromboembolic events, 32 systemic and 39 venous, occurr

59 had little impact on the findings for venous thromboembolic events (431 [0.9%] versus 461 [1.0%], OR

60 not significantly reduce the risk of venous thromboembolic events (465 [0.9%] statin versus 521 [1.0

61 Thromboembolic events (5 [7%] vs 4 [6%]) and mean (SD) c

62 rotocol-defined withdrawal criteria (11 [4%] thromboembolic events, 5 [2%] exceeding liver enzyme thr

63 Rates of thromboembolic events (6%) and hepatobiliary adverse eve

64 g muscles and/or joints (8/11), vascular and thromboembolic events (6/11), that is, deep vein thrombo

65 r complications (8.6% vs 0.1%; P=0.037), and thromboembolic events (8.6% vs 6.0%; P=0.037) were highe

66 requirements without increasing the risk of thromboembolic events across a wide variety of liver tra

67 Here, we describe the vascular and thromboembolic events afflicting a series of 40 patients

68 the incidence of LAA thrombus formation and thromboembolic events after LAAI.

69 dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve i

70 factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve r

71 Regarding safety, neither thromboembolic events among mothers nor Tpo-RA-related f

72 The rate of thromboembolic events among patients with coronavirus di

73 site endpoint of HIT-specific complications (thromboembolic events, amputation, skin necrosis) occurr

74 Three thromboembolic events and 1 major bleeding event occurre

75 ants and antiplatelet medications to prevent thromboembolic events and access thrombosis in dialysis

76 The safety outcomes were thromboembolic events and all-cause mortality within 30

77 , patients with paroxysmal AF suffered fewer thromboembolic events and deaths compared with those wit

78 orted in 29 of 113 participants (25.7%) with thromboembolic events and in 11 of 34 participants (32.4

79 Background Thromboembolic events and intraoperative rupture are the

80 Thromboembolic events and intraoperative rupture were re

81 toring and self-adjusting therapy have fewer thromboembolic events and lower mortality than those who

82 an increased incidence of cardiovascular and thromboembolic events and more deaths during the initial

83 optical density; had a higher prevalence of thromboembolic events and reached platelet count nadir l

84 Data regarding the risk of thromboembolic events and stroke after LAAI are sparse.

85 In the main trial, the risk of death or thromboembolic events and the risk of life-threatening,

86 low-up, 6 patients (4.4%) had a postreversal thromboembolic event, and 20 patients (14.6%) died.

87 lower risk of coronary heart disease, venous thromboembolic event, and cerebrovascular disease than i

88 liver toxicity, two respiratory failure, one thromboembolic event, and one sudden death).

89 ents (AEs), such as intracranial hemorrhage, thromboembolic event, and progressive aortic insufficien

90 osis and the incidence of malignancy, venous thromboembolic events, and cardiovascular disease.

91 including severe heart failure, arrhythmias, thromboembolic events, and death, the majority of women

92 very, persistent heart failure, arrhythmias, thromboembolic events, and death.

93 afety end point was a composite of bleeding, thromboembolic events, and death.

94 ile (adverse events, serious adverse events, thromboembolic events, and deaths) was similar between g

95 as not apparent for emergencies unrelated to thromboembolic events, and did not occur in a control gr

96 nd estrogen-progestin increased the risk for thromboembolic events, and etidronate increased the risk

97 Gastrointestinal side effects, hot flashes, thromboembolic events, and infections vary among drugs.

98 h) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular even

99 were no acute neurological complications, no thromboembolic events, and no bleeding complications.

100 ment-related deaths, second primary cancers, thromboembolic events, and peripheral neuropathy.

101 heart failure, hospitalization, arrhythmia, thromboembolic events, and reintervention).

102 rse events; raloxifene and estrogen increase thromboembolic events; and estrogen causes additional ad

103 rhythmias (aOR: 12.4; 95% CI: 11.0 to 14.0), thromboembolic events (aOR: 2.4; 95% CI: 2.0 to 2.9), pr

104 ma samples obtained from patients with prior thromboembolic events are denser and less susceptible to

105 Prophylaxis against and treatment of thromboembolic events are necessary and should consider

106 A substantial number of patients at risk for thromboembolic events are not anticoagulated, and furthe

107 The proportion of patients with arterial thromboembolic events as defined by the Antiplatelet Tri

108 of bleeding and the composite of bleeding or thromboembolic events at 1 year were significantly less

109 Patients with AF also may have thromboembolic events at higher INR levels.

110 ing or thromboembolism, patients with AF had thromboembolic events at higher international normalized

111 Arterial thromboembolic events (ATE) have been described with the

112 vents, but focused on the subset of arterial thromboembolic events (ATEs), comprising CV death, myoca

113 reactions; 2.6 for urticaria; 0.2 for venous thromboembolic events, autoimmune disorders, and Guillai

114 essment must address each patient's risk for thromboembolic events balanced against the risk for peri

115 reful case-by-case analysis of the risks for thromboembolic events balanced by the risks for anticoag

116 morrhage or hydrocephalus upon follow-up CT, thromboembolic events before discharge, and the 3-month

117 In conclusion, the risk of arterial thromboembolic events begins to increase 150 days before

118 imator was used to compare risks of arterial thromboembolic events between cancer and noncancer group

119 There were no differences in thromboembolic events between the groups (22 [6.0%] vs 3

120 im of this study was to compare the risk for thromboembolic events, bleeding, and mortality associate

121 collect prospective multicenter outcomes of thromboembolic events, bleeding, and mortality for patie

122 arboplatin, as were hypertension, infection, thromboembolic events, bleeding, and postoperative compl

123 hospitalization, but no increase in risks of thromboembolic events, bleeding-related hospitalization,

124 d thrombin activity underlies obesity-linked thromboembolic events, but the mechanistic links between

125 1.60 [CI, 1.15 to 2.23]; 2 trials) increase thromboembolic events by 4 to 7 per 1000 women per year;

126 ble electronic devices and increased risk of thromboembolic events, clinical intervention for device-

127 ll and major bleeding and at similar risk of thromboembolic events compared to nonbridged patients.

128 nd raloxifene were associated with increased thromboembolic events compared with placebo; tamoxifen w

129 se statin therapy reduced the risk of venous thromboembolic events compared with standard dose statin

130 eriprocedural risk of complications, such as thromboembolic events, compared to warfarin discontinuat

131 CTDa was associated with higher rates of thromboembolic events, constipation, infection, and neur

132 Thromboembolic events contribute greatly to morbidity an

133 UC]); incidence of breast cancer, fractures, thromboembolic events, coronary heart disease events, st

134 The major adverse events were thromboembolic events, corticosteroid-related morbidity,

135 nced grade 3 to 4 toxicity, and 10 (20%) had thromboembolic events (deep venous thrombosis or pulmona

136 e, myocardial infarction, and other arterial thromboembolic events defined by the Antiplatelet Triali

137 agnosis codes were used to identify arterial thromboembolic events, defined as a composite of myocard

138 utropenia grade 3 or 4: 21% vs 5%, P < .001; thromboembolic events despite aspirin prophylaxis: 23.5%

139 ic events outline a significant reduction in thromboembolic events, driven by a reduction in deep vei

140 f TTP-related death, recurrence of TTP, or a thromboembolic event during the treatment period; and a

141 f TTP-related death, recurrence of TTP, or a thromboembolic event during the trial treatment period;

142 than enoxaparin in the prevention of venous thromboembolic events during a period of immobilization

143 ted for unpublished information about venous thromboembolic events during follow-up.

144 diagnostic strategy, defined as adjudicated thromboembolic events during the 3-month follow-up perio

145 o evaluate the previously reported excess of thromboembolic events during the 30 days after the end o

146 stroke and non-central nervous system (CNS) thromboembolic events early after discontinuation of riv

147 ade 4 adverse event in the placebo group was thromboembolic event (eight [<1%]) and the most common g

148 postmenopausal women and had lower risks of thromboembolic events, endometrial cancer, and cataracts

149 center, PREFER in AF (European Prevention of thromboembolic events-European Registry in Atrial Fibril

150 s population for prophylaxis or treatment of thromboembolic events for 64 years.

151 There was a higher incidence of thromboembolic events for the transfusion threshold of 1

152 here show that systemic hypoxia accelerates thromboembolic events, functionally stimulated by the ac

153 for fractures but increased risk for stroke, thromboembolic events, gallbladder disease, and urinary

154 For patients at high risk for thromboembolic events, guidelines recommend bridging the

155 ll as 2-year risk of death, hospitalization, thromboembolic events, heart failure (HF), and AF progre

156 Outcome was a composite of thromboembolic events, heart failure hospitalizations, v

157 c electronic device implantation, infection, thromboembolic event, hemodialysis, and readmission).

158 bioprostheses have an elevated early risk of thromboembolic events; however, the risks and benefits o

159 There was one grade 3 thromboembolic event in the combination arm and one inte

160 nths in patients experiencing a first venous thromboembolic event in the setting of major, transient

161 There was no difference in the risk of thromboembolic events in 8 studies comparing bridged and

162 ed with a transient increased risk of venous thromboembolic events in a community setting.

163 d Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

164 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

165 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

166 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

167 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

168 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

169 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation [ARISTOTLE]

170 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial (ARIS

171 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial who r

172 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, pat

173 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.

174 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.

175 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).

176 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; n=18 201)

177 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; n=18 201),

178 systematically identified symptomatic venous thromboembolic events in both trials.

179 The risk of thromboembolic events in heart failure patients is estim

180 a-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.

181 Consequently, the prevention of thromboembolic events in LA positives might improve surv

182 b and bevacizumab may contribute to systemic thromboembolic events in patients aged 65 years or older

183 agents, addresses challenges with preventing thromboembolic events in patients at high risk and descr

184 Semuloparin reduces the incidence of thromboembolic events in patients receiving chemotherapy

185 ar-weight heparin aims to reduce the risk of thromboembolic events in patients receiving long-term vi

186 egarding the effectiveness and occurrence of thromboembolic events in patients treated with prothromb

187 e and efficacious in preventing bleeding and thromboembolic events in patients undergoing AF ablation

188 4-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointes

189 Diabetes is a known risk predictor for thromboembolic events in patients with atrial fibrillati

190 E constituted 11.5% of clinically recognized thromboembolic events in patients with atrial fibrillati

191 ent are largely the same as those predicting thromboembolic events in patients with atrial fibrillati

192 erapy is the standard therapy for preventing thromboembolic events in patients with atrial fibrillati

193 Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, ir

194 rophylactic anticoagulation and treatment of thromboembolic events in patients with hepatic insuffici

195 of thrombus formation leading to significant thromboembolic events in patients with nonvalvular atria

196 The incidence of thromboembolic events in the 48 hours after ablation was

197 30) and trend toward more cardiovascular and thromboembolic events in the NCRT group (P=0.069).

198 We reported a significant reduction in thromboembolic events in the self-monitoring group (haza

199 Platelet reactivity predisposes to thromboembolic events in the setting of atherosclerotic

200 ade 5 adverse events, including two arterial thromboembolic events, in the bevacizumab group, and 14

201 fter a median of 17 months, death or a first thromboembolic event (intention-to-treat analysis) had o

202 e modest increases in rates of hypertension, thromboembolic events, intestinal perforation, and neutr

203 levant safety end points, including arterial thromboembolic events, MI, stroke or transient ischemic

204 es, but tamoxifen increased the incidence of thromboembolic events more than raloxifene by 4 cases in

205 ositis (none vs four [10%] vs one [3%]), and thromboembolic event (none vs three [8%] vs two [5%]).

206 g the first cycle of therapy, and one venous thromboembolic event occurred during the study.

207 A major thromboembolic event occurred in 1 patient (0.3%) in the

208 A single thromboembolic event occurred in each of the dabigatran

209 Postreversal thromboembolic events occurred in 10 (5%) patients at 30

210 Death from cardiovascular causes or thromboembolic events occurred in 17 patients (3.4%) in

211 Thromboembolic events occurred in 26 patients (7.0%) in

212 Thromboembolic events occurred in 4 subjects receiving d

213 Thromboembolic events occurred in 73 of 7118 bridged pat

214 Thromboembolic events occurred in one patient receiving

215 ring days 1-720, ten (1.2% per patient year) thromboembolic events occurred in the Fiix-PT group vers

216 e death, one nonfatal stroke, and two venous thromboembolic events occurred in the upadacitinib group

217 Arterial thromboembolic events occurred in three patients (6.8%).

218 Thromboembolic events occurred less often in the raloxif

219 Three thromboembolic events occurred within 3 days (one in the

220 es or major adverse cardiac events including thromboembolic events occurred.

221 Reported thromboembolic events occurring in patients administered

222 and nonsignificant lower risk of stroke and thromboembolic events (odds ratio =0.61, 95% confidence

223 There was no difference in thromboembolic events (odds ratio, 0.30; 95% CI, 0.04-2.

224 mly assigned patients with an annual risk of thromboembolic events of 5% or more to continued warfari

225 ertension of grade 2 or higher (25% vs. 2%), thromboembolic events of grade 3 or higher (8% vs. 1%),

226 Thromboembolic events on dabigatran led to early termina

227 s in the combination arm experienced serious thromboembolic events (one death).

228 rom study for drug-associated toxicity (five thromboembolic events, one bowel perforation).

229 e on treatment efficacy, the impact of fatal thromboembolic events, optimal anticoagulation therapy,

230 There was no difference in rates of thromboembolic events or other complications between the

231 d up to the time of intracranial hemorrhage, thromboembolic event, or progressive aortic insufficienc

232 nfections, herpes zoster, malignancy, venous thromboembolic events, or deaths were reported; one seri

233 first 24 hours and incidence of rebleeding, thromboembolic events, or mortality.

234 ct of bariatric surgery on long-term risk of thromboembolic events outline a significant reduction in

235 e aortic insufficiency (P=0.078) but not for thromboembolic event (P=0.638).

236 erebrovascular disease (P<0.001), and venous thromboembolic events (P<0.001) than those reporting doi

237 ase duration; hemoglobin level; frequency of thromboembolic events, palpable splenomegaly, and splene

238 ere were 0.75 major bleeding events and 0.28 thromboembolic events per patient year of follow-up.

239 -hospital mortality or complications (major: thromboembolic event, pneumonia, sepsis, stroke, or myoc

240 (survival free of any nonsurgical bleeding, thromboembolic event, pump thrombosis, or neurological e

241 Thromboembolic event rates differed markedly in non-anti

242 We explored the variation in thromboembolic event rates in a non-anticoagulated AF po

243 Thromboembolic events secondary to rupture or erosion of

244 e frequent clinical complications, including thromboembolic events, seizures, fluctuations in neurolo

245 paroid (where available) reduces the risk of thromboembolic events, some of which may be life-threate

246 Emergency visits for thromboembolic events spanning 1-4 years before treatmen

247 had lower risk-adjusted all-cause mortality, thromboembolic events, subsequent depression, alcoholism

248 ial fibrillation (AF) have increased risk of thromboembolic events such as stroke and myocardial infa

249 s finding the optimal equilibrium to prevent thromboembolic events, such as stent thrombosis and thro

250 The high incidence of thromboembolic events suggests an important role of COVI

251 No thrombotic or thromboembolic events, systemic allergic reactions (incl

252 primary breast cancer but increase risk for thromboembolic events (tamoxifen, raloxifene), endometri

253 This study evaluated the incidence of thromboembolic events (TE) in post-LAAEI cases "on" and

254 Thrombotic/thromboembolic events (TEE) have been reported with plas

255 termine the incidence of venous and arterial thromboembolic events (TEEs) in patients treated with ci

256 ied a boxed safety warning about the risk of thromboembolic events (TEEs), with TEEs reported in 0.5%

257 14 [10%]), skin rash (one [1%] vs 22 [16%]), thromboembolic events (ten [7%] vs 11 [8%]), lethargy (t

258 e predictive value of stroke risk scores for thromboembolic events (TEs) after catheter ablation of a

259 s with atrial fibrillation (AF), the risk of thromboembolic events (TEs) is variable and is influence

260 malignancy are at increased risk for venous thromboembolic events (TEs).

261 nd atrial fibrillation are at higher risk of thromboembolic events than patients with heart failure a

262 We identified 685 validated thromboembolic events that occurred during 32,721 person

263 Secondary outcomes were the number of major thromboembolic events, the number of days free from coma

264 Thirty-one percent had thromboembolic events; thromboelastography parameters di

265 i-Platelet Trialists' Collaboration arterial thromboembolic events through W96.

266 ially be used to predict the risk of diverse thromboembolic events under physiological and pathologic

267 cer patients were diagnosed with an arterial thromboembolic event vs 413 (0.11%) controls (odds ratio

268 is are associated with lower rates of venous thromboembolic events (VTE), major bleeding, and superfi

269 However, because the excess risk of venous thromboembolic events (VTEs) with cisplatin-based chemot

270 ality, stroke, myocardial infarction, venous thromboembolic events (VTEs), and hypertension.

271 ty, accounts for the highest rates of venous thromboembolic events (VTEs).

272 for cardiovascular safety, only one further thromboembolic event was reported (fatal pulmonary embol

273 et Trialists' Collaboration-defined arterial thromboembolic events was 1.9%, 0.9%, 1.1%, 2.1%, and 1.

274 The number of patients with venous thromboembolic events was 158 (4.0%) of 3958 with availa

275 A lower incidence of combined thromboembolic events was also observed with antiplatele

276 For pulmonary embolism, history of previous thromboembolic events was identified as the only risk fa

277 proportional reporting of syncope and venous thromboembolic events was noted with data mining methods

278 ving oral anticoagulation, bleeding, but not thromboembolic events, was increased in patients with li

279 sient ischemic attack (TIA), or a peripheral thromboembolic event were randomly assigned to undergo c

280 Patient characteristics, warfarin use, and thromboembolic events were ascertained from clinical dat

281 f hospitalizations for bleeding and arterial thromboembolic events were estimated in an intent-to-tre

282 l events, cerebrovascular events, and venous thromboembolic events were estimated to be 19.6%, 21.6%,

283 Factors associated with thromboembolic events were female sex (odds ratio [OR],

284 Risk factors for thromboembolic events were female sex and middle cerebra

285 nosis, the interval 30-day risks of arterial thromboembolic events were higher in cancer patients vs

286 Thromboembolic events were lower in the ruxolitinib grou

287 neurysm coiling or balloon-assisted coiling, thromboembolic events were more frequent than were intra

288 events and 33 and 58 and 12 and 28 arterial thromboembolic events were observed during follow-up, re

289 No thromboembolic events were observed during the study.

290 Arterial thromboembolic events were reported in 5.6% of the patie

291 Thromboembolic events were significantly increased with

292 nosis, the 30-day interval risks of arterial thromboembolic events were similar between cancer patien

293 raventricular hemorrhage, hydrocephalus, and thromboembolic events were similar between groups.

294 Thromboembolic events were the likely cause of various c

295 diagnosis and seven of those had documented thromboembolic event while on extracorporeal membrane ox

296 hagic and ischemic stroke, or between venous thromboembolic events with or without pulmonary embolism

297 Prevention of thromboembolic events with oral anticoagulants in nephro

298 sulted in a 28% reduction in fatal and major thromboembolic events without a significant increase in

299 risk of venous and arterial fatal and major thromboembolic events without significantly increasing m

300 sociated with significantly fewer deaths and thromboembolic events, without increased risk for a seri